The company announced 7.35 million shares of its Class A common stock, the release said. Prices are expected to be between $16 and $18 per share. Bioventus expects to grant underwriters a 30-day option to buy an additional 1.1 million shares of common stock after the initial public offering.
The company filed an initial common offering with the Securities and Exchange Commision Jan. 19. It filed an IPO in 2016 but withdrew its application two months later.
More articles on biologics:
$35M spine hospital with ASC planned for Louisiana
X-Stop vs. laminectomy in lumbar spinal stenosis: 5 things to know
4 CEO moves at orthopedic practices in 2021
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
